Slide 1: Cupid Limited
CUPID LIMITED Manufacturer & Exporter of Male Condoms, Female Condoms, Water based Lubricants & In Vitro Diagnostics (IVD) Kits § Date: - 31st January, 2024 To, § Department of Corporate Services, The National Stock Exchange of India Ltd. g BSE LIMITED, Exchange Plaza, 5" Floor, Bandra-Kurla Phiroze
Slide 2: Q3FY24 Investor Presentation
CUPID LIMITED Q3FY24 INVESTOR PRESENTATION
Slide 3: Index
Index About the Company 5 Capacity Expansion 14 Our Vision 6 Powering the Business 15 Key Facts & Figures 7 Overview of our products 17 Our Journey 8 Male Condoms 18 Global Reach ` 9 Female Condoms 19 Technical Capabilities & Quality Practices 10 Lubricant Jelly 20 In-House Laboratory 11 In-Vitro Di
Slide 4: Safe Harbour Statement
Safe Harbour Statement This presentation and the accompanying slides (the “Presentation”), which have been prepared by Cupid Limited (Cupid, The Company) solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and sha
Slide 5: Company Overview
Company Overview
Slide 6: About the Company
About the Company Established in 1993, CUPID Limited is India's premier manufacturer of male and female condoms, personal lubricant, and IVD kits. The company boasts a production capacity of up to 480 million male condoms, 52 million female condoms, 210 million sachets of personal lubricant and 20 m
Slide 7: Our Vision
FIGHT AGAINST Our HIV/AIDS We at Cupid Limited are committed to play a promising role for the fight against HIV/AIDS & Vision Prevention of Unintended Pregnancy. Developing a safe and effective methodology against HIV is critical to our efforts to control the devastating pandemic of HIV/AIDS as WE H
Slide 8: Key Facts & Figures
Key Facts & Figures First Company to have Over 2 decades Presence in WHO/UNFPA Prequalification for of experience 90+ countries both Male & Female Condoms World class German manufacturing technology for Strong export factory spread over condom business 100000 sq ft. manufacturing Staff with an avera
Slide 9: Our Journey
From Humble Beginnings to Global Success Our Journey 1990 2016 TO TO 2000 2021 2006-07 2016 2022-23 1993 Expanded capacity from 160 Launched Cupid brand in India, Commenced IVD Device Company Incorporation Mn to 400 Mn. began making water-based manufacturing operations. 1995 lubricant jelly, and got
Slide 10: Global Reach
Africa Asia Global South Africa, Kenya Rwanda, Zimbabwe, Indonesia, Burma, UAE, Nepal, Sri Reach Ghana, Nigeria, Gabon, Benin, Ivory Coast, Uganda, Congo, Cameroon, Burundi, Comoros, Guinea Bissau, Morocco, Central Lanka, Syria, Bhutan, DRC, Tajikistan, Uzbekistan, Jordan, Pakistan, Kuwait, Afghanis
Slide 11: Technical Capabilities & Quality Practices
Technical Capabilities & QUALITY PRACTICES 02 Exemplary Manufacturing Flawless Execution 01 World Class manufacturing facility in Established operating procedures and conformity with global standards and defined processes to ensure zero best quality practices defect quality 03 04 Cutting-Edge Precis
Slide 12: In-house Laboratory
Freedom of Holes In-house Laboratory Dimensions Burst Volume & Burst Pressure Equipped for Comprehensive Quality Testing Lubricant Package Seal 3 Stages of Testing integrity Quality In-coming raw & packaging material testing In-process product testing Finished product testing Visual Packaging & Defe
Slide 13: Certifications
Setting the CE 2460 BRAZIL ANVISA bar high! ISO 14001:2015 ISO 13485:2016 SABS MARK Our Quality Standard ISO 9001:2015 Certifications! ISO 9001:2015 We boast of exceptional products supported by credible certifications, affirming their high quality and standards USFDA (510K) FOR UN FPA- MALE CONDOMS
Slide 14: World-Class Manufacturing Facility
World-Class 100000 SQ. FT AREA Manufacturing Facility 480M PIECES MALE CONDOM German Dipping Technology & Electronic Testing 52M PIECES FEMALE CONDOM 210M SACHETS PER YEAR LUBRICANT JELLY Manufacturing unit in Sinnar, Nashik about 200 km, East of Mumbai 24M PIECES IVD KITS PER YEAR
Slide 15: Capacity Expansion
Capacity Expansion LAND INCREASE IN PRODUCTION STATE OF THE ACQUISITION CAPACITY EXPANSION ART MACHINERY Acquisition of a new land Increase in capacity by 1.5 Total Capacity post expansion: The company plans to invest in parcel in the coveted MIDC times the existing output. the capacity for male con
Slide 16: Powering Our Business
POWERING OUR BUSINESS OUR STRONG IN-HOUSE MANUFACTURING CAPABILITIES Dipping Section Testing Section Sealing Section IVD Section Female Condom Lubricant Quality Testing Section Jelly Section Lab Section
Slide 17: Business Overview
Business Overview
Slide 18: Overview of Our Products
Overview of Our Products MALE CONDOM FEMALE CONDOM LUBRICANT JELLY IVD KITS Extra Large Condoms Made up of Latex Water based Lubricant jelly Foray into medical devices which Extra Strong Condoms 100% Indian made and is to be used with includes Rapid Diagnostic Tests Ultra-Thin Condoms costs consider
Slide 19: Male Condoms
Male CONDOMS SIZES : Rectangular, Square & Circular format. TYPES : Plain, Dotted, Ribbed, Multi-textured, Extra Strong, Extra Large & Ultra-Thin. Male Condoms are available in different varieties like Plain, Dotted, Ribbed, Multi- textured, Extra Strong, Extra Large & UltraThin. They are also avail
Slide 20: Female Condoms
Female CONDOMS BRANDS DEVELOPED: Condomise Cupid Female Condom, Securite Plus, Ormelle Female Condom, i-Pill Female Condom, Pee Safe Domina Cupid Female Condom commercial production started in 2010. Cupid Female Condoms are available with or without flavor and color. INSTALLED CAPACITY OF 52 MILLION
Slide 21: Lubricant Jelly
Lubricant JELLY Water based Lubricant Jelly is used with condoms to enhance pleasure. Cupid Limited started manufacturing lubricant jelly in 2015. Water based Lubricants are available in different pack sizes starting from 4.5ml sachets, Laminated Tubes and bottles. Currently Lubricants are being exp
Slide 22: In Vitro Diagnostic Devices
In Vitro Diagnostic Devices VIRAL TRANSPORT SYPHILIS AB TEST HIV 1 & 2 AB TEST MEDIUM TYPHOID IgG/IgM TEST Chromatographic Chromatographic Intended use: for the Chromatographic immunoassay immunoassay collection and transport of immunoassay Detection of Specific TP Detection of HIV 1 & 2 clinical sp
Slide 23: In Vitro Diagnostic Devices
In Vitro Diagnostic Devices MALARIA PF-PAN AG HEPATITIS B (HBSAG) MALARIA PF-PV AG HEPATITIS C (HCV) AB TEST AG TEST TEST TEST Chromatographic Chromatographic Chromatographic Chromatographic immunoassay immunoassay immunoassay immunoassay Detection of Pf-HRP II and Detection of Hepatitis B Detection
Slide 24: In Vitro Diagnostic Devices
In Vitro Diagnostic Devices PREGNANCY HCG DENGUE IGG-IGM AB LH OVULATION RAPID DENGUE NS1 ANTIGEN DETECTION TEST TEST TEST TEST KIT Chromatographic Chromatographic Chromatographic Chromatographic immunoassay immunoassay immunoassay immunoassay Detection of HCG levels Detects Dengue Antibodies Detect
Slide 25: Management Overview
Management Overview
Slide 26: Core Management Team
Core Management Team He belongs to the promoter group He has 4 decades of experience in petrochemical industry & Petroleum Executive Director Mr. Kuldeep Halwasiya Specialty Oils & Chairman He is the Promoter & CMD of Columbia Petro Chem Pvt Ltd., which operates an installed capacity of 4 Lakh KLPA
Slide 27: Professional & Experienced Management
Professional & Experienced Management He a leading corporate lawyer with specialization in securities market, banking and finance, Mr. Rajinder Independent infrastructure projects and regulatory advice. Singh Loona Director He has served as Executive Director (Law) of Securities & Exchange Board of
Slide 28: Industry Overview
Industry Overview
Slide 29: Global Markets: Market Size of Male & Female Condoms
Market Size of Male & Female Condoms Global Markets 98.8% 1.2% Male Female The global condom market size was Condoms Condoms valued at USD 10.7 billion in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 8.57% from 2023 to 2030. The condom product market is divided into male
Slide 30: Overview on Female Condoms
Overview on Female Condoms The female condom segment is estimated to witness the fastest growth of 12.69% compound annual growth rate (CAGR) during the forecast period. Female condoms are increasingly being accepted by females who are serious about reducing risk of STIs and unplanned pregnancy. The
Slide 31: Global Condom Market Growth Drivers
Global Condom Market Global Growth Drivers North America Europe Asia Pacific Latin America Middle East & Africa Latin America North America 8.4% 12% Rising awareness regarding the use of condoms The availability of different types of condoms to suit consumer needs Europe 25.5% Measures to reduce the
Slide 32: India's Condom Market
India’s Condom Market: Trends And Opportunities For Grow India’s Condom Market The Indian Condom market is expected The market is estimated to grow with a North Zone is expected to lead the to reach US$ 508.36 Mn in 2027 from CAGR of 12.2% from 2019-2027. market in the India owing to the US$ 183.46
Slide 33: India's Growth Drivers
India’s Growth Drivers The rising awareness in the number of people Increasing use of locally manufactured condoms Presence of a robust distribution network High density of adult and middle aged population
Slide 34: Financial Overview
Financial Overview
Slide 35: Standalone Financial Statement Highlights
Standalone Financial Particulars (Rs. Crores except EPS) Q3FY24 Q2FY24 QoQ% Q3FY23 Statement Highlights Revenue from Operations 40.05 34.46 16% 41.76 Total Expenses excluding Depreciation, 27.9 29.24 28.85 Amortization & Finance Cost Q3FY24 vs Q2FY24 vs Q3FY23 EBITDA 12.15 5.22 132% 12.91 EBITDA Mar
Slide 36: Balance Sheet
*Rs. Crores Balance Sheet EQUITY & LIABILITIES As at 31 December 2023 As at 31 March 2023 ASSETS As at 31 December 2023 As at 31 March 2023 EQUITY Non-current assets Equity Share capital 13.34 13.34 Property, Plant and Equipment 36.25 36.00 Other Equity 167.16 153.78 Capital Work In Progress - - Tot
Slide 37: Financial Highlights
Financial Highlights Revenue From Operations (in Rs. Cr) EBITDA (in Rs. Cr) PAT (in Rs. Cr) 50 14 EBITDA Margin (%) 12 PAT Margin (%) 12.91 12.15 41.76 12 10.03 40.05 10 40 30.91% 30.34% 8.86 16% 24.02% 34.46 10 8 22.12% 30 8 6 5.11 6 5.22 20 4 4 15.15% 14.83% 10 2 2 0 0 0 Q3FY23 Q2FY24 Q3FY24 Q3FY2
Slide 38: Segment Information for the Quarter
Segment Information for the Quarter Segment Revenue Segment Results Profit/(Loss) Before Tax In Vitro Devices (IVD) Other/ Unallocated 2.6% Other/ Unallocated In Vitro Devices (IVDs) 6.20% 1.8% (1.03%) Male and Female Contraceptives & Jelly Male and Female Contraceptives & Jelly 95.6% 94.83%
Slide 39: Capital Markets Data
24 30-Ja n 3,000,000 1,000,000 1,500,000 2,000,000 0 500,000 2,500,000 02 -Ja -23 - n 07 Fe -23 - b 10 Fe -23 - b 15 Fe -23 b 20-Fe -2 b 3 23-Fe -23 b 28-Fe -23 b 03-Fe -2 b 3 09-Ma -2 - r 3 14 Ma -23 - r 17 Ma -23 - r 45.1% 22 Ma -23 - r 27 Ma -23 - r 31 Ma -23 - r 06 Ma -23 -A r-2 Promoter & Promo
Slide 40: Thank You
Thank You Investor Relations Advisor: Brijesh K. Impress Strategic Communications Private Limited Email: cupid@impressir.com